Literature DB >> 18726895

Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.

C William Helm1, Robert E Bristow, Shigeki Kusamura, Dario Baratti, Marcello Deraco.   

Abstract

Women with epithelial ovarian cancer (EOC) usually present with advanced disease and overall only just over half survive 5 years. Even following a complete response to front-line treatment two-thirds will recur, with a resultant dismal prognosis. We review and discuss the role of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in EOC and present the results of the ovary consensus panel (OCP) convened for the 5th International Workshop on Peritoneal Surface Malignancy.

Entities:  

Mesh：

Year:  2008        PMID： 18726895     DOI： 10.1002/jso.21083

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  15 in total

Review 1.  Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Authors:  Ramez N Eskander; James Cripe; Robert E Bristow
Journal:  Curr Treat Options Oncol       Date:  2014-03

Review 2.  The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.

Authors:  E Saladino; F Fleres; S Irato; C Famulari; A Macrì
Journal:  Updates Surg       Date:  2013-08-27

Review 3.  Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

Authors:  Terence C Chua; Greg Robertson; Winston Liauw; Rhonda Farrell; Tristan D Yan; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-23       Impact factor: 4.553

4.  Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites.

Authors:  Mingchen Ba; Hui Long; Xiangliang Zhang; Yunqiang Tang; Yinbing Wu; Feihong Yu; Shuai Wang; Shuzhong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-22       Impact factor: 4.553

5.  Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.

Authors:  Clarisse S Muenyi; Allan R Pinhas; Teresa W Fan; Guy N Brock; C William Helm; J Christopher States
Journal:  Toxicol Sci       Date:  2012-02-13       Impact factor: 4.849

6.  Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells.

Authors:  Clarisse S Muenyi; Abhaya P Trivedi; C William Helm; J Christopher States
Journal:  Toxicol Sci       Date:  2014-02-11       Impact factor: 4.849

Review 7.  Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes.

Authors:  Harveshp Mogal; Konstantinos Chouliaras; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  J Gastrointest Oncol       Date:  2016-02

8.  Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites.

Authors:  Ming-Chen Ba; Hui Long; Shu-Zhong Cui; Yun-Qiang Tang; Yin-Bing Wu; Xiang-Liang Zhang; Hong-Sheng Tang; Sai-Xi Bai
Journal:  Surg Endosc       Date:  2013-02-08       Impact factor: 4.584

9.  Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Clarisse S Muenyi; Vanessa A States; Joshua H Masters; Teresa W Fan; C William Helm; J Christopher States
Journal:  J Ovarian Res       Date:  2011-06-22       Impact factor: 4.234

10.  Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study.

Authors:  Antonio Macrì; Fabio Accarpio; Vincenzo Arcoraci; Francesco Casella; Franco De Cian; Pierandrea De Iaco; Elena Orsenigo; Franco Roviello; Giovanni Scambia; Edoardo Saladino; Marica Galati
Journal:  Pleura Peritoneum       Date:  2020-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.